Home > Gastroenterology > Antihyperglycemic drugs likely effective for NAFLD

Antihyperglycemic drugs likely effective for NAFLD


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Journal
The Lancet Gastroenterology and Hepatology
Reuters Health - 26/01/2022 - Three different classes of antihyperglycemic drugs - PPAR agonists, GLP-1R agonists and SGLT2 inhibitors - showed promise in treating non-alcoholic fatty liver disease (NAFLD) in a systematic review.  "Although our systematic review...supports the efficacy of PPAR agonists or GLP-1R agonists in improving histological features of non-alcoholic steatohepatitis (NASH), as well as the efficacy of SGLT2 inhibitors in reducing hepatic fat content, we believe that larger phase 3 trials with liver histological endpoints (some of which are ongoing) are needed to consider changes in current guidelines," Dr. Alessandro Mantovani of the University Hospital of Verona told Reuters Health by email.


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on